A Phase 2/3 interventional study of SHR-1703 and Mepolizumab Injection in Eosinophilic Granulomatosis With Polyangiitis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.
61 studies on the registry are indexed under Churg-Strauss Syndrome; 17 are open to participants now.
This study's planned enrollment of 166 is above the median of 66 across 30 interventional studies indexed under Churg-Strauss Syndrome.
Browse Churg-Strauss Syndrome studies →Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SHR-1703
Drug: SHR-1703
SHR-1703 Placebo
Drug: Mepolizumab Injection
SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
Mepolizumab Injection and Matching Placebo will be administered by Subcutaneous injection in Phase 3
Change from baseline in oral glucocorticoid dose (OCS)
Phase 2
Time frame: Up to week 12
The Proportion of subjects in EGPA remission
Phase 3
Time frame: week 36 and week 48
Change from baseline in oral glucocorticoid dose
Effectiveness Indicators (Phase 2)
Time frame: Up to week 24, week 48
The proportion of subjects with OCS dosage ≤5 mg/d
Effectiveness Indicators (Phase 2)
Time frame: week 12, week 24, week 48
The proportion of subjects with at least 50% reduction of OCS dosage from baseline
Effectiveness Indicators (Phase 2)
Time frame: week 12, week 24, week 48
The Proportion of subjects with EULAR remission
Effectiveness Indicators (Phase 2)
Time frame: week 12, week 24, week 48
The Proportion of subjects achieving EULAR remission at week 12 and week 24 of treatment and maintaining it up to week 48
Effectiveness Indicators (Phase 2)
Time frame: week 12, week 24, week 48
The Proportion of subjects with EGPA remission
Effectiveness Indicators (Phase 2)
Time frame: week 24, week 48
The proportion of subjects achieving EGPA remission within 24 weeks of treatment and maintaining it up to week 48
Effectiveness Indicators (Phase 2)
Time frame: week 24, week 48
The proportion of subjects with EGPA relapse
Effectiveness Indicators (Phase 2)
Time frame: week 12, week 24, week 48
The time to the first relapse of EGPA
Effectiveness Indicators (Phase 2)
Time frame: Up to week 48
The proportion of subjects with Severe relapse of EGPA
Effectiveness Indicators (Phase 2)
Time frame: week 12, week 24, week 48
The time of the first Severe relapse of EGPA
Effectiveness Indicators (Phase 2)
Time frame: Up to week 48
Changes from baseline in Pre- and post-Bronchodilator FEV1
Effectiveness Indicators (Phase 2)
Time frame: Up to week 48
The Proportion of subjects with EULAR remission
Effectiveness Indicators (Phase 3)
Time frame: week 36, week 48
The Proportion of subjects with EGPA remission
Effectiveness Indicators (Phase 3)
Time frame: week 36, week 48
The Proportion of subjects achieving EULAR remission within 24 weeks of treatment and maintaining it up to week 48
Effectiveness Indicators (Phase 3)
Time frame: week 24, week 48
The proportion of subjects achieving EGPA remission within 24 weeks of treatment and maintaining it up to week 48
Effectiveness Indicators (Phase 3)
Time frame: week 24, week 48
Cumulative weeks of EGPA remission through week 48, categorized as 0 weeks; >0 to <12 weeks; 12 to <24 weeks; 24 to <36 weeks; or ≥36 weeks
Effectiveness Indicators (Phase 3)
Time frame: week 0, week 12, week 24, week 36, week 48
Change from baseline in OCS
Effectiveness indicators (Phase 3)
Time frame: Week 24, Week 48
The proportion of subjects with OCS dosage ≤5 mg/d
Effectiveness indicators (Phase 3)
Time frame: week 24, week 48
The proportion of subjects with at least 50% reduction of OCS dosage from baseline
Effectiveness indicators (Phase 3)
Time frame: week 24, week 48
The Proportion of subjects with EGPA relapse
Effectiveness indicators (Phase 3)
Time frame: week 24, week 48
The Proportion of subjects with Severe relapse of EGPA
Effectiveness indicators (Phase 3)
Time frame: week 24, week 48
The time to the first relapse of EGPA
Effectiveness indicators (Phase 3)
Time frame: Up to week 48
The time of the first Severe relapse occurred of EGPA
Effectiveness indicators (Phase 3)
Time frame: Up to week 48
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Dec 2028, 61 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SHR-1703
Guangdong Hengrui Pharmaceutical Co., Ltd →